About Us

Our Team: Committed to moving the field of microbiome therapeutics forward

  • Joe Trebley, Ph.D

    Founder & Chief Executive Officer

    Dr. Trebley is Co-founder and CEO of Scioto Biosciences and Monon Bioventures.

    Read More
  • Jim Schulz, CPA

    Founder and Chief Financial Officer

    Mr. Schulz is a serial entrepreneur with over 20 years of financial experience working with public accounting firms, Fortune 500 companies and small start-up companies.

    Read More
  • Mark Heiman, Ph.D

    Chief Science Officer

    Mark L. Heiman, Ph.D. has 20+ years at Eli Lilly & Co where he served as researcher and CSO of obesity drug discovery. 

    Read More
  • Kevin Meyer

    Chief Operating Officer

    Kevin Meyer has over 10 years of experience in the life sciences industry, having invented, patented, and commercialized a diverse portfolio of technologies.

    Read More
  • Jaswant Gidda, Ph.D

    Preclinical and Toxicology Advisor

    Jaswant S. Gidda, Ph. D. has extensive drug discovery and development experience in big pharma (Eli Lilly & Co) and as an entrepreneur in biotechnology industry.

    Read More
  • Rob Houghtaling

    Director of Business Development and Strategy

    Rob joined Scioto Biosciences in 2018 as the Director of Business Development and Strategy. Rob brings broad strategy and transaction advisory experience across the biopharma industry

    Read More
  • Micah Mackison

    Board Member

    Mr. Mackison has over 15 years of pharmaceutical and life sciences experience in corporate development and strategy, mergers and acquisitions and finance.

    Read More
  • Graeme Martin

    Graeme Martin, Ph.D

    Graeme Martin. Ph.D is an industry veteran with an extensive track record in multinational Pharmaceutical R&D

    Read More
  • Jim Schulz, CPA

    Founder and Chief Financial Officer

    Mr. Schulz is a serial entrepreneur with over 20 years of financial experience working with public accounting firms, Fortune 500 companies and small start-up companies.

    Read More
  • Brian Stemme

    Brian Stemme, Project Director

    Brian Stemme is project director for BioCrossroads. He has a strong background in life sciences market development and research.

    Read More
  • Joe Trebley, Ph.D

    FOUNDER & CHIEF EXECUTIVE OFFICER

    Dr. Trebley is Co-founder and CEO of Scioto Biosciences and Monon Bioventures.

    Read More
  • Gail E. Besner, M.D.

    Gail E. Besner, M.D.

    As a surgeon and scientist, Gail E. Besner, M.D., joined Nationwide Children’s Hospital and The Ohio State University in 1991 upon completion of her pediatric surgical training.

    Read More
  • Steve Goodman, Ph.D

    Scientific Founder

    Since 2012, Dr. Goodman has been the  principal investigator in the Center for Microbial Pathogenesis.

    Read More
  • Michael Bailey, Ph.D.

    Scientific Founder

    Studies in Dr. Bailey's laboratory focus on determining the impact that the intestinal microbiota have on the local mucosal immune system, and on immune reactivity at systemic sites, particularly during periods of psychological stress.

    Read More
  • Lauren Bakaletz, Ph.D.

    Scientific Founder

    Lauren O. Bakaletz, Ph.D. is a Professor of both Pediatrics and Otolaryngology and serves as Director of the Center for Microbial Pathogenesis at The Research Institute at Nationwide Children’s Hospital in Columbus, OH.

    Read More

Revolutionizing Therapeutic Interventions

By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.

Erosion of the physical mucus barrier leads to breaches and penetration of toxins, proteins and microbiota to enterocytes of the intestine. The result is collectively termed “leaky gut” and is often associated with low levels of chronic GI and systemic inflammation.

Enabling the delivery of active, live therapeutic bacteria capable of persisting in the gut and primed for adhesion to intestinal mucosa using our ABT technology will serve several unmet medical needs when applied as an intervention to fortify the mucosal barrier in states where breaches are documented.

Therapeutic Interventions